U.S. Markets closed

Royalty Pharma plc (RPRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
42.13+0.20 (+0.48%)
At close: 04:00PM EST
42.13 0.00 (0.00%)
After hours: 04:51PM EST

Royalty Pharma plc

110 East 59th Street
New York, NY 10022
United States
212 883 0200

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Pablo Gerardo LegorretaFounder, Chairman & CEO49.51MN/A1964
Mr. Terrance P. CoyneExec. VP & CFO3.9MN/AN/A
Mr. George Wingate LloydExec. VP of Investments & Chief Legal Officer3.9MN/A1959
Mr. Christopher HiteVice Chairman & Exec. VP4.01MN/A1967
Dr. Marshall Urist M.D., Ph.D.Exec. VP and Head of Research & Investments3.55MN/AN/A
Mr. Arthur R. McGivern J.D.Exec. VP of Investments & Gen. CounselN/AN/AN/A
Ms. Kristin StaffordSr. VP & Chief Accounting OfficerN/AN/AN/A
Dr. James Folmar Reddoch Ph.D.Exec. VP of Investments & Chief Scientific OfficerN/AN/A1970
Mr. George Grofik C.F.A., CPASr. VP and Head of Investor Relations & CommunicationsN/AN/AN/A
Ms. Alessandra SassunVP & Head of Human CapitalN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Corporate Governance

Royalty Pharma plc’s ISS Governance QualityScore as of October 1, 2022 is 5. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 6; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.